180 related articles for article (PubMed ID: 33839273)
21. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
[TBL] [Abstract][Full Text] [Related]
22. Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis.
Visrodia K; Singh S; Krishnamoorthi R; Ahlquist DA; Wang KK; Iyer PG; Katzka DA
Gastroenterology; 2016 Mar; 150(3):599-607.e7; quiz e14-5. PubMed ID: 26619962
[TBL] [Abstract][Full Text] [Related]
23. Progression of Barrett's esophagus, crypt dysplasia, and low-grade dysplasia diagnosed by wide-area transepithelial sampling with 3-dimensional computer-assisted analysis: a retrospective analysis.
Shaheen NJ; Smith MS; Odze RD
Gastrointest Endosc; 2022 Mar; 95(3):410-418.e1. PubMed ID: 34537193
[TBL] [Abstract][Full Text] [Related]
24. The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus.
Nguyen T; Thrift AP; Yu X; Duan Z; El-Serag HB
Am J Gastroenterol; 2017 Jul; 112(7):1049-1055. PubMed ID: 28244499
[TBL] [Abstract][Full Text] [Related]
25. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
[TBL] [Abstract][Full Text] [Related]
26. Practice patterns of surveillance endoscopy in a Veterans Affairs database of 29,504 patients with Barrett's esophagus.
El-Serag HB; Duan Z; Hinojosa-Lindsey M; Hou J; Shakhatreh M; Naik AD; Chen GJ; Street RL; Kramer JR
Gastrointest Endosc; 2012 Oct; 76(4):743-55. PubMed ID: 22985642
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes in patients with a diagnosis of "indefinite for dysplasia" in Barrett's esophagus: a multicenter cohort study.
Sinh P; Anaparthy R; Young PE; Gaddam S; Thota P; Balasubramanian G; Singh M; Higbee AD; Wani S; Gupta N; Rastogi A; Mathur SC; Bansal A; Horwhat JD; Cash BD; Falk GW; Lieberman DA; Vargo JJ; Sampliner RE; Sharma P
Endoscopy; 2015 Aug; 47(8):669-74. PubMed ID: 25910065
[TBL] [Abstract][Full Text] [Related]
28. Use of Appropriate Surveillance for Patients With Nondysplastic Barrett's Esophagus.
Tavakkoli A; Appelman HD; Beer DG; Madiyal C; Khodadost M; Nofz K; Metko V; Elta G; Wang T; Rubenstein JH
Clin Gastroenterol Hepatol; 2018 Jun; 16(6):862-869.e3. PubMed ID: 29432922
[TBL] [Abstract][Full Text] [Related]
29. Persistent indefinite for dysplasia in Barrett's esophagus is a risk factor for dysplastic progression to low-grade dysplasia.
Henn AJ; Song KY; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
Dis Esophagus; 2020 Sep; 33(9):. PubMed ID: 32399569
[TBL] [Abstract][Full Text] [Related]
30. Neoplasia Detection Rate in Barrett's Esophagus and Its Impact on Missed Dysplasia: Results from a Large Population-Based Database.
Dhaliwal L; Codipilly DC; Gandhi P; Johnson ML; Lansing R; Wang KK; Leggett CL; Katzka DA; Iyer PG
Clin Gastroenterol Hepatol; 2021 May; 19(5):922-929.e1. PubMed ID: 32707339
[TBL] [Abstract][Full Text] [Related]
31. Yield of Repeat Endoscopy for Barrett's Esophagus After Normal Index Endoscopy.
Rubenstein JH; Burns JA; Arasim ME; Firsht EM; Harbrecht M; Widerquist M; Evans RR; Inadomi JM; Chang JW; Hazelton WD; Hur C; Kurlander JE; Lim F; Luebeck G; Macdonald PW; Reddy CA; Saini SD; Tan SX; Waljee AK; Lansdorp-Vogelaar I
Am J Gastroenterol; 2023 Jul; 118(7):1168-1174. PubMed ID: 36716445
[TBL] [Abstract][Full Text] [Related]
32. Predictors of dysplastic and neoplastic progression of Barrett’s esophagus.
Alnasser S; Agnihotram R; Martel M; Mayrand S; Franco E; Ferri L
Can J Surg; 2019 Apr; 62(2):93-99. PubMed ID: 30907564
[TBL] [Abstract][Full Text] [Related]
33. Barrett's surveillance identifies patients with early esophageal adenocarcinoma.
Wong T; Tian J; Nagar AB
Am J Med; 2010 May; 123(5):462-7. PubMed ID: 20399324
[TBL] [Abstract][Full Text] [Related]
34. Independent Validation of a Tissue Systems Pathology Assay to Predict Future Progression in Nondysplastic Barrett's Esophagus: A Spatial-Temporal Analysis.
Frei NF; Konte K; Bossart EA; Stebbins K; Zhang Y; Pouw RE; Critchley-Thorne RJ; Bergman JJGHM
Clin Transl Gastroenterol; 2020 Oct; 11(10):e00244. PubMed ID: 33108124
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.
Wani S; Rubenstein JH; Vieth M; Bergman J
Gastroenterology; 2016 Nov; 151(5):822-835. PubMed ID: 27702561
[TBL] [Abstract][Full Text] [Related]
36. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
[TBL] [Abstract][Full Text] [Related]
37. Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma.
Solanky D; Krishnamoorthi R; Crews N; Johnson M; Wang K; Wolfsen H; Fleischer D; Ramirez FC; Katzka D; Buttar N; Iyer PG
J Clin Gastroenterol; 2019; 53(5):361-365. PubMed ID: 29608452
[TBL] [Abstract][Full Text] [Related]
38. Dysplasia in Random Biopsies from Barrett's Surveillance Is an Important Marker for More Severe Pathology.
Noordzij IC; Van Loon van de Ende MCM; Curvers WL; van Lijnschoten G; Huysentruyt CJ; Schoon EJ
Dig Dis Sci; 2021 Jun; 66(6):1957-1964. PubMed ID: 32661766
[TBL] [Abstract][Full Text] [Related]
39. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
[TBL] [Abstract][Full Text] [Related]
40. Development of Evidence-Based Surveillance Intervals After Radiofrequency Ablation of Barrett's Esophagus.
Cotton CC; Haidry R; Thrift AP; Lovat L; Shaheen NJ
Gastroenterology; 2018 Aug; 155(2):316-326.e6. PubMed ID: 29655833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
